EASI ≤7 response rate
Fig. 4. · Panel EASI_7
Panel EASI_7 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Diamant Thaçi, Luis Puig, Sei-Ichiro Motegi, Kim Papp, Linda Stein Gold, Leon Kircik, Howard Sofen, Pablo Fernández-Peñas, Pedro Herranz, Christian Vestergaard, Yu-Huei Huang, Martin Dossenbach, Hany Elmaraghy, Gaia Gallo, Maria Jose Rueda, Marta Casillas, Chao Yang, Helena Agell, Meritxell Falqués, Audrey Nosbaum
Acta Derm Venereol 106 0160
The ADvocate trials (NCT04146363, NCT04178967) investigated adults/adolescents with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab (LEB) monotherapy, using percent improvement in the Eczema Area and Severity Index (EASI). In clinical trials, percent EASI improvement is used to compare study arms and measure treatment effect size/impact. In clinical practice, however, absolute EASI scores are used (especially in Europe), as they measure an individual's disease state regardless of baseline severity. This post-hoc analysis assessed absolute EASI response - EASI≤7, ≤5, ≤3, and ≤1 - from the ADvocate trials to understand LEB efficacy in adults/adolescents with moderate-to-severe AD. Week-16 data from patients receiving LEB 250 mg Q2W (n=564) were compared with placebo (n=287). Across baseline moderate/severe/very severe EASI and baseline Investigator's Global Assessment (IGA) 3/4, significantly higher percentages of patients receiving LEB than those receiving placebo achieved each absolute EASI response. Week--16 LEB EASI 75 responders (n=284) and per-protocol LEB non-responders (n=215) were assessed through week 52. Absolute EASI scores were generally low and stable among responders and reduced among non-responders. Overall, LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Results reflect clinically meaningful improvements that could help guide clinical practice.
1 个 Figure · 4 个 KM 面板
Fig. 4.. Response rates at week 52 among week-16 EASI 75 LEB responders. Each chart compares EASI response rates among week-16 EASI 75 LEB responders who were re-randomized into two LEB treatment arms and one LEB withdrawal arm. Data from weeks 16–52 are provided. Week-16 EASI 75 LEB responders who received systemic rescue medication, discontinued treatment due to lack of efficacy or transferred to the escape arm had values set to their baseline value after that time point through week 52. Those who received topical rescue medication or discontinued treatment for other reasons had values set to “missing” after that time point through week 52. Multiple imputation was used to handle missing data. Abbreviations: EASI, eczema area and severity index; LEB, lebrikizumab; Q2W, every 2 weeks; Q4W, every 4 weeks.
Fig. 4. · Panel EASI_7
Panel EASI_7 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. · Panel EASI_5
Panel EASI_5 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. · Panel EASI_3
Panel EASI_3 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. · Panel EASI_1
Panel EASI_1 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。